



UEMS ACCREDITATION:

The course in “**Dyslipidaemias present and future approaches to pharmacological intervention**”, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 8 European CME credits (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

The breakdown of ECMEC®s per day:

09.11.2019 - 5.00

10.11.2019 - 3.00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

EAS have independently organised all matters related to this Programme, including content and presenters.

SCIENTIFIC SECRETARIAT:

SITeCS - Società Italiana di Terapia Clinica e Sperimentale v ia Balzaretti, 7- 20133 Milano
tel: +39 02 49636373 - fax: +39 02 49633384
e-mail: segreteria@sitecs.it
web: www.sitecs.it

ORGANIZING SECRETARIAT:

Delos Communication srl
p.co Comola Ricci, 98 - 80122 Naples
Tel: +39 081 7142129; Fax: +39 081 7141472
e-mail: info@deloscommunication.it
web: www.deloscommunication.it

MEETING VENUE

Hilton Sorrento Palace
Via Sant'Antonio, 13
80067 Sorrento NA, Italy

Dyslipidaemias: Present and Future Approaches to Pharmacological Intervention

November 9th-10th, Sorrento (NA) - Italy

Chairs: Alberico L. Catapano, Lale Tokgözoğlu

Thanks to unconditional support from

Scientific Program

November 9th, 2019

09.00 Registration

INTRODUCTION

CHAIRS Lale Tokgözoğlu, Alberico L. Catapano

10.00 **Introduction and scope of the meeting**

PREVENTION: WHEN SHOULD WE START?

CHAIRS Lale Tokgözoğlu, Alberico L. Catapano

10.20 **Early intervention for future benefit** Matteo Pirro

10.40 **Discussion**

NON PHARMACOLOGICAL THERAPEUTIC APPROACHES

CHAIRS Maciej Banach, Carlos Escobar

11.00 **Lifestyle interventions** Carlos Escobar

11.20 **Role of nutraceuticals** Maciej Banach

11.40 **Updates of the clinical evidences** Arrigo G. Cicero

12.00 **Discussion**

12.45 **Lunch**

LIPOPROTEINS AND ATHEROSCLEROSIS

CHAIRS Laura Calabresi, Alberico L. Catapano

13.45 **What does low HDL-C mean?** Laura Calabresi

14.15 **ApoB a common denominator?** Brian Ference

14.45 **TG lowering benefit: Clinical evidence** Alberto Zambon

15.15 **Discussion**

DYSLIPIDEMIA MANAGEMENT: The New 2019 EAS/ESC guidelines

CHAIR Lale Tokgözoğlu

15.45 **ESC/EAS 2019** Alberico L. Catapano, Lale Tokgözoğlu

16.30 **Coffee break**

CURRENT AND FUTURE THERAPEUTIC APPROACHES

CHAIRS Alberico L. Catapano, Lale Tokgözoğlu

17.00 **Statins** Lale Tokgözoğlu

17.20 **Ezetimibe and combination therapy** Luis Masana

17.40 **PCSK9 inhibitors** Michel Farnier

18.00 **Novel therapeutic approaches** Alberico L. Catapano

18.20 **Discussion**

19.00 **Wrap up**

November 10th, 2019

PRESENTATION AND DISCUSSION OF CLINICAL CASES

CHAIRS Pasquale P. Filardi, Francesco Rossi, Lale Tokgözoğlu

08.30 **Low Risk (<1% and LDL >140 mg/dL)**

Matteo Pirro, Maciej Banach

09.00 **Initial state of Diabetes, medium-high risk, high TG**

Alberto Zambon, Lluís Masana

09.30 **High risk patient, with CKD, in primary prevention**

Laura Calabresi, Arrigo G. Cicero

10.00 **High risk patient, with FH, in primary prevention**

Lale Tokgözoğlu, Michel Farnier

10.30 **High risk patient, Acute Coronary Syndrome**

Carlos Escobar, Pasquale Perrone Filardi

11.00 **Discussion**

12.00 **Conclusion**

DYSLIPIDAEMIAS PRESENT AND FUTURE APPROACHES TO PHARMACOLOGICAL INTERVENTION

November 9th-10th, Sorrento (NA) - Italy

CHAIRS

Alberico L. Catapano
Pasquale Perrone Filardi
Francesco Rossi
Lale Tokgözoğlu

FACULTY

Maciej Banach
Luis Masana
Laura Calabresi
Pasquale P. Filardi
Alberico L. Catapano
Matteo Pirro
Arrigo G. Cicero
Francesco Rossi
Carlos Escobar
Lale Tokgözoğlu
Michel Farnier
Alberto Zambon
Brian Ference